Early detection of poor adherers to statins: applying individualized surveillance to pay for performance.

Medication nonadherence costs $300 billion annually in the US. Medicare Advantage plans have a financial incentive to increase medication adherence among members because the Centers for Medicare and Medicaid Services (CMS) now awards substantive bonus payments to such plans, based in part on populat...

Full description

Bibliographic Details
Main Authors: Andrew J Zimolzak, Claire M Spettell, Joaquim Fernandes, Vincent A Fusaro, Nathan P Palmer, Suchi Saria, Isaac S Kohane, Magdalena A Jonikas, Kenneth D Mandl
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3817130?pdf=render
_version_ 1818764760320049152
author Andrew J Zimolzak
Claire M Spettell
Joaquim Fernandes
Vincent A Fusaro
Nathan P Palmer
Suchi Saria
Isaac S Kohane
Magdalena A Jonikas
Kenneth D Mandl
author_facet Andrew J Zimolzak
Claire M Spettell
Joaquim Fernandes
Vincent A Fusaro
Nathan P Palmer
Suchi Saria
Isaac S Kohane
Magdalena A Jonikas
Kenneth D Mandl
author_sort Andrew J Zimolzak
collection DOAJ
description Medication nonadherence costs $300 billion annually in the US. Medicare Advantage plans have a financial incentive to increase medication adherence among members because the Centers for Medicare and Medicaid Services (CMS) now awards substantive bonus payments to such plans, based in part on population adherence to chronic medications. We sought to build an individualized surveillance model that detects early which beneficiaries will fall below the CMS adherence threshold.This was a retrospective study of over 210,000 beneficiaries initiating statins, in a database of private insurance claims, from 2008-2011. A logistic regression model was constructed to use statin adherence from initiation to day 90 to predict beneficiaries who would not meet the CMS measure of proportion of days covered 0.8 or above, from day 91 to 365. The model controlled for 15 additional characteristics. In a sensitivity analysis, we varied the number of days of adherence data used for prediction.Lower adherence in the first 90 days was the strongest predictor of one-year nonadherence, with an odds ratio of 25.0 (95% confidence interval 23.7-26.5) for poor adherence at one year. The model had an area under the receiver operating characteristic curve of 0.80. Sensitivity analysis revealed that predictions of comparable accuracy could be made only 40 days after statin initiation. When members with 30-day supplies for their first statin fill had predictions made at 40 days, and members with 90-day supplies for their first fill had predictions made at 100 days, poor adherence could be predicted with 86% positive predictive value.To preserve their Medicare Star ratings, plan managers should identify or develop effective programs to improve adherence. An individualized surveillance approach can be used to target members who would most benefit, recognizing the tradeoff between improved model performance over time and the advantage of earlier detection.
first_indexed 2024-12-18T08:07:19Z
format Article
id doaj.art-163b50a468784cdc9f5121e1b83f3882
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-18T08:07:19Z
publishDate 2013-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-163b50a468784cdc9f5121e1b83f38822022-12-21T21:14:58ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-01811e7961110.1371/journal.pone.0079611Early detection of poor adherers to statins: applying individualized surveillance to pay for performance.Andrew J ZimolzakClaire M SpettellJoaquim FernandesVincent A FusaroNathan P PalmerSuchi SariaIsaac S KohaneMagdalena A JonikasKenneth D MandlMedication nonadherence costs $300 billion annually in the US. Medicare Advantage plans have a financial incentive to increase medication adherence among members because the Centers for Medicare and Medicaid Services (CMS) now awards substantive bonus payments to such plans, based in part on population adherence to chronic medications. We sought to build an individualized surveillance model that detects early which beneficiaries will fall below the CMS adherence threshold.This was a retrospective study of over 210,000 beneficiaries initiating statins, in a database of private insurance claims, from 2008-2011. A logistic regression model was constructed to use statin adherence from initiation to day 90 to predict beneficiaries who would not meet the CMS measure of proportion of days covered 0.8 or above, from day 91 to 365. The model controlled for 15 additional characteristics. In a sensitivity analysis, we varied the number of days of adherence data used for prediction.Lower adherence in the first 90 days was the strongest predictor of one-year nonadherence, with an odds ratio of 25.0 (95% confidence interval 23.7-26.5) for poor adherence at one year. The model had an area under the receiver operating characteristic curve of 0.80. Sensitivity analysis revealed that predictions of comparable accuracy could be made only 40 days after statin initiation. When members with 30-day supplies for their first statin fill had predictions made at 40 days, and members with 90-day supplies for their first fill had predictions made at 100 days, poor adherence could be predicted with 86% positive predictive value.To preserve their Medicare Star ratings, plan managers should identify or develop effective programs to improve adherence. An individualized surveillance approach can be used to target members who would most benefit, recognizing the tradeoff between improved model performance over time and the advantage of earlier detection.http://europepmc.org/articles/PMC3817130?pdf=render
spellingShingle Andrew J Zimolzak
Claire M Spettell
Joaquim Fernandes
Vincent A Fusaro
Nathan P Palmer
Suchi Saria
Isaac S Kohane
Magdalena A Jonikas
Kenneth D Mandl
Early detection of poor adherers to statins: applying individualized surveillance to pay for performance.
PLoS ONE
title Early detection of poor adherers to statins: applying individualized surveillance to pay for performance.
title_full Early detection of poor adherers to statins: applying individualized surveillance to pay for performance.
title_fullStr Early detection of poor adherers to statins: applying individualized surveillance to pay for performance.
title_full_unstemmed Early detection of poor adherers to statins: applying individualized surveillance to pay for performance.
title_short Early detection of poor adherers to statins: applying individualized surveillance to pay for performance.
title_sort early detection of poor adherers to statins applying individualized surveillance to pay for performance
url http://europepmc.org/articles/PMC3817130?pdf=render
work_keys_str_mv AT andrewjzimolzak earlydetectionofpooradhererstostatinsapplyingindividualizedsurveillancetopayforperformance
AT clairemspettell earlydetectionofpooradhererstostatinsapplyingindividualizedsurveillancetopayforperformance
AT joaquimfernandes earlydetectionofpooradhererstostatinsapplyingindividualizedsurveillancetopayforperformance
AT vincentafusaro earlydetectionofpooradhererstostatinsapplyingindividualizedsurveillancetopayforperformance
AT nathanppalmer earlydetectionofpooradhererstostatinsapplyingindividualizedsurveillancetopayforperformance
AT suchisaria earlydetectionofpooradhererstostatinsapplyingindividualizedsurveillancetopayforperformance
AT isaacskohane earlydetectionofpooradhererstostatinsapplyingindividualizedsurveillancetopayforperformance
AT magdalenaajonikas earlydetectionofpooradhererstostatinsapplyingindividualizedsurveillancetopayforperformance
AT kennethdmandl earlydetectionofpooradhererstostatinsapplyingindividualizedsurveillancetopayforperformance